Boxer Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-3,201,440
| Closed | -$188M | – | 65 |
|
|
2023
Q4 | $188M | Hold |
3,201,440
| – | – | 9.37% | 1 |
|
|
2023
Q3 | $139M | Buy |
3,201,440
+1,201,440
| +60% | +$42.9M | 7.42% | 1 |
|
|
2023
Q2 | $72.3M | Hold |
2,000,000
| – | – | 3.35% | 8 |
|
|
2023
Q1 | $74.4M | Hold |
2,000,000
| – | – | 3.65% | 9 |
|
|
2022
Q4 | $90.6M | Hold |
2,000,000
| – | – | 4.78% | 5 |
|
|
2022
Q3 | $140M | Hold |
2,000,000
| – | – | 7.86% | 1 |
|
|
2022
Q2 | $134M | Hold |
2,000,000
| – | – | 8.5% | 1 |
|
|
2022
Q1 | $164M | Hold |
2,000,000
| – | – | 8.45% | 1 |
|
|
2021
Q4 | $293M | Hold |
2,000,000
| – | – | 11.39% | 1 |
|
|
2021
Q3 | $354M | Hold |
2,000,000
| – | – | 12.36% | 1 |
|
|
2021
Q2 | $323M | Hold |
2,000,000
| – | – | 11.4% | 1 |
|
|
2021
Q1 | $343M | Buy |
2,000,000
+234,440
| +13% | +$46.4M | 11.62% | 1 |
|
|
2020
Q4 | $388M | Hold |
1,765,560
| – | – | 12.47% | 1 |
|
|
2020
Q3 | $293M | Hold |
1,765,560
| – | – | 10.13% | 3 |
|
|
2020
Q2 | $202M | Hold |
1,765,560
| – | – | 8.86% | 2 |
|
|
2020
Q1 | $136M | Buy |
1,765,560
+50,000
| +3% | +$4.48M | 9.25% | 1 |
|
|
2019
Q4 | $221M | Hold |
1,715,560
| – | – | 12.5% | 1 |
|
|
2019
Q3 | $134M | Hold |
1,715,560
| – | – | 9.69% | 2 |
|
|
2019
Q2 | $177M | Hold |
1,715,560
| – | – | 15.19% | 1 |
|
|
2019
Q1 | $126M | Buy |
1,715,560
+150,000
| +10% | +$10.2M | 14.54% | 1 |
|
|
2018
Q4 | $66.4M | Hold |
1,565,560
| – | – | 8.21% | 5 |
|
|
2018
Q3 | $73.7M | Hold |
1,565,560
| – | – | 8.18% | 5 |
|
|
2018
Q2 | $77.2M | Buy |
1,565,560
+193,050
| +14% | +$7.29M | 8.74% | 3 |
|
|
2018
Q1 | $42.1M | Hold |
1,372,510
| – | – | 4.5% | 9 |
|
|
2017
Q4 | $25M | Buy |
1,372,510
+334,516
| +32% | +$5.19M | 4.58% | 7 |
|
|
2017
Q3 | $12.1M | Hold |
1,037,994
| – | – | 2.76% | 11 |
|
|
2017
Q2 | $3.79M | Hold |
1,037,994
| – | – | 0.9% | 18 |
|
|
2017
Q1 | $5.4M | Buy |
1,037,994
+280,059
| +37% | +$1.53M | 1.18% | 14 |
|
|
2016
Q4 | $3.6M | Hold |
757,935
| – | – | 1.39% | 13 |
|
|
2016
Q3 | $5.01M | Hold |
757,935
| – | – | 2.25% | 13 |
|
|
2016
Q2 | $4.14M | Hold |
757,935
| – | – | 3.67% | 13 |
|
|
2016
Q1 | $16.2M | Sell |
757,935
-1,265,297
| -63% | -$28.3M | 15.87% | 1 |
|
|
2015
Q4 | $63.9M | Buy |
+2,023,232
| New | +$71.5M | 55.2% | 1 |
|
Other funds holding MRTX
Boxer Capital's MRTX Position: Q1 2024 in Review
Boxer Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 3,201,440 shares — an estimated $188M sold.
Boxer Capital first reported a position in MRTX in Q4 2015 and held it in 33 quarters. The position peaked at $388M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Boxer Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Boxer Capital sold 3,201,440 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $188M.
- Boxer Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 33 quarters.
- Boxer Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $388M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Boxer Capital's 13F filing for Q1 2024, filed 15 May 2024.